
Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
The Job of a Migration Legal advisor: How They Can Help You - 2
Germany's far-right AfD tops poll ahead of Merz's conservatives - 3
These Cities Led Global Jet-Setting In 2025, According To New Data - 4
Watch Atlas V rocket launch its heaviest-ever payload early on April 4 - 5
NASA will bring space station crew home early after medical issue
The secret appeal of Harlan Coben’s messy, addictive TV thrillers
Step by step instructions to Get a good deal on Your Rooftop Substitution Venture
Vote In favor of Your Favored Occasion Arranging Administration
Holyvolt And Wildcat Could Help The West Reclaim Battery Leadership
A trip to Colombia in my 20s turned into 8 years freelancing in South America. Here's what I'd do differently.
The Secret Side of Italy: 12 Underrated Destinations Locals Don’t Want Tourists to Find
False fuel prices in fabricated graphics circulate in Malaysia as Iran war continues
Apartment Turned Into Nightmare 'Ice Castle' After Tenant Shut Off Heat Causing Pipes to Burst: VIDEO
Disability rights activist and author Alice Wong dies at 51













